Fenfluramine Hydrochloride Patent Expiration
Fenfluramine Hydrochloride is used for reducing or ameliorating seizures in patients with Dravet or Lennox-Gastaut syndrome through various combination therapies and cardiac monitoring to mitigate cardiovascular risk. It was first introduced by Ucb Inc
Fenfluramine Hydrochloride Patents
Given below is the list of patents protecting Fenfluramine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Fintepla |
US10452815 (Pediatric) | Control system for control of distribution of medication | Dec 29, 2038 | Ucb Inc |
| Fintepla | US10452815 | Control system for control of distribution of medication | Jun 29, 2038 | Ucb Inc |
| Fintepla |
US10603290 (Pediatric) | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Feb 02, 2038 | Ucb Inc |
| Fintepla |
US11040018 (Pediatric) | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Feb 02, 2038 | Ucb Inc |
| Fintepla |
US11406606 (Pediatric) | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Feb 02, 2038 | Ucb Inc |
| Fintepla |
US11759440 (Pediatric) | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Feb 02, 2038 | Ucb Inc |
| Fintepla |
US11786487 (Pediatric) | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Feb 02, 2038 | Ucb Inc |
| Fintepla | US10603290 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Aug 02, 2037 | Ucb Inc |
| Fintepla | US11040018 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Aug 02, 2037 | Ucb Inc |
| Fintepla | US11406606 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Aug 02, 2037 | Ucb Inc |
| Fintepla | US11759440 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Aug 02, 2037 | Ucb Inc |
| Fintepla | US11786487 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | Aug 02, 2037 | Ucb Inc |
| Fintepla |
US10947183 (Pediatric) | Fenfluramine compositions and methods of preparing the same | Jun 20, 2037 | Ucb Inc |
| Fintepla | US10947183 | Fenfluramine compositions and methods of preparing the same | Dec 20, 2036 | Ucb Inc |
| Fintepla |
US10950331 (Pediatric) | Control system for control of distribution of medication | Mar 28, 2036 | Ucb Inc |
| Fintepla | US10950331 | Control system for control of distribution of medication | Sep 28, 2035 | Ucb Inc |
| Fintepla |
US10478441 (Pediatric) | Method for the treatment of Dravet syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla |
US10478442 (Pediatric) | Method for the treatment of Dravet Syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla |
US12097206 (Pediatric) | Method for the treatment of Dravet Syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla |
US9549909 (Pediatric) | Method for the treatment of dravet syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla |
US9603814 (Pediatric) | Method for the treatment of Dravet syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla |
US9603815 (Pediatric) | Method for the treatment of Dravet syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla |
US9610260 (Pediatric) | Method for the treatment of Dravet Syndrome | Nov 03, 2033 | Ucb Inc |
| Fintepla | US10478441 | Method for the treatment of Dravet syndrome | May 03, 2033 | Ucb Inc |
| Fintepla | US10478442 | Method for the treatment of Dravet Syndrome | May 03, 2033 | Ucb Inc |
| Fintepla | US12097206 | Method for the treatment of Dravet Syndrome | May 03, 2033 | Ucb Inc |
| Fintepla | US9549909 | Method for the treatment of dravet syndrome | May 03, 2033 | Ucb Inc |
| Fintepla | US9603814 | Method for the treatment of Dravet syndrome | May 03, 2033 | Ucb Inc |
| Fintepla | US9603815 | Method for the treatment of Dravet syndrome | May 03, 2033 | Ucb Inc |
| Fintepla | US9610260 | Method for the treatment of Dravet Syndrome | May 03, 2033 | Ucb Inc |
Fenfluramine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Fenfluramine Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome | UCB BIOSCIENCES, Inc. | NA |
COMPLETED
(Sep 1, 2026)
| PHASE3 |
| A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome | UCB BIOSCIENCES, Inc. | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder. | Zogenix, Inc. | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE3 |